From rapid diagnostics to biopharmaceuticals — see how Sekbio solved real challenges for leading companies across APAC and beyond.
Browse Case StudiesSelect a category or view all projects. Click any card to see the full case details.
Existing CHO cell line yielding only 2 g/L. Commercial viability required ≥ 5 g/L. Previous optimization attempts had failed.
Needed validated antibody pairs for a 5-plex STI lateral flow diagnostic. Tight QC standards, 6-week commercial deadline.
Custom anti-PD-L1 with specific epitope targeting required. Publication deadline in 3 months; conventional development timeline was 6 months.
Needed rapid 1 L HEK293 scale-up with <1 EU/mL endotoxin for IND-enabling studies. Timeline: 4 weeks from gene sequence.
Two previous vendors failed to produce functional bispecific antibody. Aggregation >60% in all prior attempts. Series A milestone at risk.
Required matched antibody pairs for simultaneous CRP and SAA measurement on CLIA analyzer. Sensitivity <0.1 mg/L for both targets.
Research lab needed high-affinity anti-NP monoclonal for ELISA and LFA development. Needed characterization data suitable for peer-reviewed publication.
Needed cTnI antibody pair with pg/mL sensitivity for fingerstick whole-blood format. Previous vendor pair had unacceptable cross-reactivity with skeletal troponin.
Required IgG1 → IgG4 isotype switch to eliminate effector function in vitreal administration context. Needed full bioactivity confirmation post-engineering.
IL-6R therapeutic candidate with persistent endotoxin contamination (>10 EU/mL) from prior vendor. Needed to maintain binding activity post-polishing.
Needed validated MxA antibody pair achieving 2 pg/mL sensitivity with >300× S/N dynamic range for whole-blood CLIA platform.
Required soluble dengue NS1 antigen (all 4 serotypes) in HEK293 for cross-reactive IgG ELISA development under tight grant deadline.
Needed stable CHO cell line producing 3+ g/L of cysteine-engineered antibody for site-specific ADC conjugation. Transient expression insufficient.
Local IVD manufacturer required HRP2-negative-strain-compatible antibody pairs after hrp2 deletion variants emerged in their target market.
Needed biotinylated CD19 ectodomain at 10 mg scale for CAR construct screening. Previous E. coli expression gave insoluble aggregates.
Required pg/mL sensitivity NT-proBNP antibody pair stable in whole-blood matrix for LFA cardiac strip. Wide linear range (5–35,000 pg/mL) needed.
Therapeutic anti-EGFR antibody with short serum half-life due to suboptimal FcRn binding. Needed YTE mutation introduction without disrupting antigen binding.
IVD kit manufacturer needed guaranteed <5% lot-to-lot signal CV for OEM antibody supply across 12-month production period. Previous vendor at 18–25% CV.
NGO partner needed cost-effective, heat-stable cholera O1 antibody pair for LFA strips deployable without cold chain in field conditions.
Therapeutic antibody production has helped pharma clients reduce development timelines by 4–6 months on average, with CHO yields up to 2.4 g/L.
From MxA to troponin to STI panels — 30+ diagnostic antibody pairs validated across CLIA, FIA, and LFA platforms for global IVD manufacturers.
Publication-grade antibodies with complete characterization data — epitope mapping, SPR kinetics, and functional assay confirmation for peer-reviewed submissions.
Started with focus on recombinant antibody expression and IVD antibody pair development for CLIA and LFA platforms.
Achieved quality management system certification for medical device components — enabling regulatory-grade documentation for all projects.
Introduced express antibody validation with a 21-day guaranteed timeline — first in the APAC region at this specification.
Reached 500+ successful projects across pharma, IVD, research, and biotech sectors, maintaining 95%+ first-attempt success rate.
CE Marking obtained. Partner network expanded to 200+ IVD brands across 30+ countries, covering APAC, Europe, and North America.
Over 800 successful projects delivered. Continuing to serve IVD and pharmaceutical clients with ISO 13485 quality and express-speed delivery.
Contact us to discuss your antibody project. Our scientists are ready to help.